As per the agreement, CDRI and Zydus will jointly undertake preclinical research, it said. Any drug candidate emerging from the efforts will be developed by Zydus for India and other markets, it added ...

After hours: September 27 at 4:07 PM EDT Loading Chart for ALTO ...

Zydus Lifesciences on Saturday said it has received approval from the US health regulator ... said the US health regulator has issued four observations after inspecting its Bengaluru-based API (active ...

Nippon India Small Cap Fund (B) 509.80 22,21,106 0.84 Nippon India Small Cap Fund (IDCW) 509.80 22,21,106 0.84 Nippon India Small Cap Fund (G) 509.80 22,21,106 0.84 ...

New Delhi: Zydus Lifesciences on Friday said it has tied up with Lucknow-based CSIR-Central Drug Research Institute (CDRI) to develop a drug for chronic kidney disease-induced osteoporosis.

Zydus Lifesciences Ltd. on Saturday said it has received approval from the U.S. health regulator to produce generic prostate cancer treatment drug. The company has received approval from the U.S. Food ...

The drug will be produced at the group's manufacturing site in Moraiya, Ahmedabad, Zydus said. As per IQVIA MAT July 2024 data, Enzalutamide capsules (40 mg) had annual sales of USD 869.4 million in ...

Zydus Lifesciences receives USFDA approval to manufacture Enzalutamide capsules (40 mg), a generic prostate cancer treatment drug. The drug will be produced at the company's Moraiya, Ahmedabad ...

After hours: September 27 at 4:20 PM EDT Loading Chart for MGPI ...

Zydus will take charge of marketing, distributing, and selling these MRI contrast agents in the US market, marking its entry into the contrast agent product category. The warning letter ...

Receipt of Order-In-Original by Zydus Healthcare Limited from Deputy Commissioner DGSTO-6, Bengaluru-Karnataka. Zydus Lifesciences Receipt Of Demand Order-In-Original By Zydus Healthcare Limited From ...